Latest & greatest articles for pravastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pravastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pravastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pravastatin

21. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). (PubMed)

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Studies have demonstrated that statins administered to individuals with risk factors for coronary heart disease (CHD) reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups.To determine whether pravastatin compared (...) cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL, were randomized to pravastatin (n = 5170) or to usual care (n = 5185). Baseline mean total cholesterol was 224 mg/dL; LDL-C, 146 mg/dL; high-density lipoprotein cholesterol, 48 mg/dL; and triglycerides, 152 mg/dL. Mean age was 66 years, 49% were women, 38% black and 23% Hispanic, 14% had a history of CHD, and 35% had type 2 diabetes.Pravastatin, 40 mg/d, vs usual care.The primary outcome was all

2002 JAMA

22. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. (PubMed)

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke.We did a randomised controlled trial in which we (...) assigned 5804 men (n=2804) and women (n=3000) aged 70-82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4.0 mmol/L to 9.0 mmol/L. Follow-up was 3.2 years on average and our primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Analysis was by intention-to-treat.Pravastatin lowered LDL cholesterol concentrations by 34

2002 Lancet

23. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective Glasziou P P, Eckermann S D, Mulray S E (...) , Simes R J, Martin A J, Kirby A C, Hall J P, Caleo S, White H D, Tonkin A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared cholesterol-lowering therapy with pravastatin with no therapy (i.e. placebo). Type

2002 NHS Economic Evaluation Database.

24. Low-density lipoprotein size, pravastatin treatment, and coronary events. (PubMed)

Low-density lipoprotein size, pravastatin treatment, and coronary events. Small low-density lipoprotein (LDL) particle size has been hypothesized to be a risk factor for coronary heart disease (CHD). Animal models link large LDL to atherosclerosis. However, the strong association between small LDL and other risk factors, particularly triglyceride levels, impedes determining whether LDL size independently predicts CHD in humans.To examine whether LDL size is an independent predictor of recurrent (...) coronary events in patients with known CHD, as opposed to a marker for other lipid abnormalities.Prospective, nested case-control study in the Cholesterol and Recurrent Events (CARE) trial, a randomized placebo-controlled trial of pravastatin conducted in 1989-1996.Survivors of myocardial infarction with typical LDL concentrations (416 cases and 421 controls).Subsequent myocardial infarction or coronary death during the 5-year follow-up, analyzed by quintile of LDL particle size and by treatment

2001 JAMA

25. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. (PubMed)

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating (...) this anti-inflammatory effect of statins are not available.To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction.Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior history of cardiovascular disease (primary prevention cohort) and open-label study including 1182 patients with known cardiovascular disease (secondary prevention cohort) who provided at least baseline and 12-week blood samples. The study

2001 JAMA

26. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. (PubMed)

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Statins inhibit the same biochemical pathway as aminobisphosphonates, therefore these cholesterol-lowering agents may have a beneficial effect on osteoporosis. This possibility has been supported by the finding that some statins also stimulate bone formation, and by observational studies suggesting that patients (...) using statins have higher bone densities and lower fracture rates than controls. To assess whether statins have clinically significant effects on bone, we studied the frequency of fractures in a large randomised controlled trial of these agents.9014 patients (17% women, median age 62 years) with ischaemic heart disease were randomly assigned pravastatin 40 mg daily or placebo and followed up for a mean of 6.0 years. Fractures were ascertained from adverse-event reports.101 patients in the placebo

2001 Lancet

27. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol

Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol Ito M K, Lin J C, Morreale A P, Marcus D B, Shabetai R, Dresselhaus T R, Henry R R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin to reduce low-density lipoprotein (LDL) cholesterol levels. Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients receiving pravastatin at a Veterans Affairs medical centre. Setting The setting

2001 NHS Economic Evaluation Database.

28. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness

Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolaemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness Cerivastatin versus branded pravastatin (...) and the conclusions drawn. Health technology Cerivastatin (third-generation statin) and branded pravastatin (first-generation statin) were evaluated for the treatment of primary hypercholesterolaemia: Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with documented primary hypercholesterolaemia that did not respond adequately to dietary interventions. The patients were aged between 18 and 75 years. The patient's

2001 NHS Economic Evaluation Database.

29. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2001 NHS Economic Evaluation Database.

30. Pravastatin therapy and the risk of stroke. (PubMed)

Pravastatin therapy and the risk of stroke. Several epidemiologic studies have concluded that there is no relation between total cholesterol levels and the risk of stroke. In some studies that classified strokes according to cause, there was an association between increasing cholesterol levels and the risk of ischemic stroke and a possible association between low cholesterol levels and the risk of hemorrhagic stroke. Recent reviews of trials of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (...) inhibitors have suggested that these agents may reduce the risk of stroke.In a double-blind trial (the Long-Term Intervention with Pravastatin in Ischaemic Disease study), we compared the effects of pravastatin on mortality due to coronary heart disease (the primary end point) with the effects of placebo among 9014 patients with a history of myocardial infarction or unstable angina and a total cholesterol level of 155 to 271 mg per deciliter (4.0 to 7.0 mmol per liter). Our goal in the present study

Full Text available with Trip Pro

2000 NEJM

31. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. (PubMed)

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. The LIPID study is a major trial of secondary prevention of coronary-heart-disease events that includes hospital admission with unstable angina (as well as myocardial infarction) as a qualifying event. In this substudy of LIPID, we compared subsequent cardiovascular risks and the effects of pravastatin in patients with previous unstable angina or previous myocardial infarction.3260 patients diagnosed (...) with unstable angina and 5754 with acute myocardial infarction 3-36 months previously were randomly assigned 40 mg pravastatin daily or placebo over a mean of 6.0 years. The risk reduction of a range of cardiovascular events was estimated by means of the hazard ratio in Cox's proportional hazards model.Among patients assigned placebo, survival in the two diagnosis groups was similar. The relative risk reduction for mortality with pravastatin was 20.6% in the myocardial infarction group and 26.3

2000 Lancet

32. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (PubMed)

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain.In a double (...) -blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease.Death

Full Text available with Trip Pro

1998 NEJM

33. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. (PubMed)

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. To estimate the economic efficiency of using pravastatin to prevent the transition from health to cardiovascular disease in men with hypercholesterolaemia.Economic benefit analysis based on data from the West of Scotland coronary prevention study. Treatment specific hazards of developing cardiovascular disease according to various definitions were estimated. Scottish record linkage (...) taking pravastatin, 318 of them would not make the transition from health to cardiovascular disease (number needed to treat, 31.4), at a net discounted cost of 20m Pounds over 5 years. These benefits imply an undiscounted gain of 2,460 years of life, and thus 8121 Pounds per life year gained, or 20,375 Pounds per life year gained if benefits are discounted. Restriction to the 40% of men at highest risk reduces the number needed to treat to 22.5 (5601 Pounds per life year gained (undiscounted

Full Text available with Trip Pro

1997 BMJ

34. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, McMurray J, Shepherd J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of pravastatin in addition to the usual lipid-lowering dietary advice in the prevention of cardiovascular disease. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Scottish men aged 45-64 years

1997 NHS Economic Evaluation Database.

35. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. (PubMed)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. In patients with high cholesterol levels, lowering the cholesterol level reduces the risk of coronary events, but the effect of lowering cholesterol levels in the majority of patients with coronary disease, who have average levels, is less clear.In a double-blind trial lasting five years we administered either 40 mg (...) of pravastatin per day or placebo to 4159 patients (3583 men and 576 women) with myocardial infarction who had plasma total cholesterol levels below 240 mg per deciliter (mean, 209) and low-density lipoprotein (LDL) cholesterol levels of 115 to 174 mg per deciliter (mean, 139). The primary end point was a fatal coronary event or a nonfatal myocardial infarction.The frequency of the primary end point was 10.2 percent in the pravastatin group and 13.2 percent in the placebo group, an absolute difference of 3

1996 NEJM

36. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease Ashraf T, Hay J W, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C D, Radican L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cholesterol lowering using pravastatin in people with Coronary Artery Disease (CAD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Male patients (n=445, mean age of 60 years) with CAD and moderately elevated serum low-density lipoprotein cholesterol. Setting The practice setting

1996 NHS Economic Evaluation Database.

37. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. (PubMed)

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease.We (...) randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points.Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent

1995 NEJM

38. Effect of pravastatin on outcomes after cardiac transplantation. (PubMed)

Effect of pravastatin on outcomes after cardiac transplantation. Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown to be effective and safe in lowering cholesterol levels after cardiac transplantation. Cell-culture studies using inhibitors of HMG-CoA reductase have suggested an immunosuppressive effect.Early after (...) transplantation, we randomly assigned consecutive patients to receive either pravastatin (47 patients) or no HMG-CoA reductase inhibitor (50 patients).Twelve months after transplantation, the pravastatin group had lower mean (+/- SD) cholesterol levels than the control group (193 +/- 36 vs. 248 +/- 49 mg per deciliter, P < 0.001), less frequent cardiac rejection accompanied by hemodynamic compromise (3 vs. 14 patients, P = 0.005), better survival (94 percent vs. 78 percent, P = 0.025), and a lower incidence

1995 NEJM

39. Replacing lovastatin with pravastatin: effect on serum lipids and costs

Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Korman L, Borysiuk L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Pravastatin. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Patients being treated with lovastatin, with an average age of 66 years. Setting Primary care. The economic study was carried out in Connecticut, USA. Dates to which data relate Costs mainly related to 1993 and were expressed in 1995 prices. Effectiveness data were collected up until October 1993. Source of effectiveness data

1995 NHS Economic Evaluation Database.

40. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. (PubMed)

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia.Double blind, double dummy, placebo controlled study with three parallel groups.Six specialist lipid clinics in the United Kingdom.128

Full Text available with Trip Pro

1992 BMJ